August 8, 2023 07:19 AM EDTUpdated 11:21 AM
Pharma

Up­dat­ed: Lil­ly's rev­enues rise 28% in Q2 thanks to surge in de­mand for di­a­betes drug Moun­jaro

Kyle LaHucik

Senior Reporter

Eli Lil­ly said its rev­enues in the sec­ond quar­ter jumped 28% year-over-year due to growth from its type 2 di­a­betes drug Moun­jaro, breast can­cer treat­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times